Total: $1,163.86M | ||||
Company | Type Of | Number | Amount | Investors; Placement Agents; Details |
Aastrom | Private | 1.88S | $2.95 | Aastrom raised $2.95M in private placements with Isosceles Fund Ltd., Radyr Group Investments and Rochelle S.A. (6/26) |
AtheroGenics | Private | 3.6S | $20.6 | AtheroGenics raised $20.6M through the sale of 3.6M shares; JPMorgan H&Q acted as placement agent; investors included SAFECO Growth Opportunities Fund and Vulcan Ventures Inc. (6/20) |
Bioniche Life | Private | N/A | C$6 | Bioniche completed the first tranche in a private placement of special warrants (6/29) |
Biopure Corp. | Equity line | N/A | _ | Biopure entered a $75M equity line stock purchase agreement with the Parisian bank Societe Generale that gives the company the option to draw funds over the next two years (6/22) |
BioTransplant | Private | 3S | $19 | BioTransplant raised $19M, placing 3M shares with institutional investors (6/7) |
Cellegy | Private | 2.7S | $15.4 | Cellegy raised $15.4M through the placement of 2.7M shares with investors Baker/Tisch Investments, GMT Capital Corp., OrbiMed Advisors, SAFECO Asset Management, First Manhattan Co., JALAA Equities and Knott Partners (6/8) |
Cell | Private | N/A | $150 | Cell Therapeutics raised $150M through the placement; each note will convert to common stock at an initial conversion price of $34 per share (6/8) |
Cephalon Inc. | Private | N/A | $100 | Cephalon's purchasers of its $300M aggregate principal amount of 5.52% convertible subordinated notes due 2006 have exercised in full their option to purchase $100M in additional notes (6/21) |
COR | Private | N/A | $250 | COR agreed to sell $250M of five-year senior notes to institutional buyers (6/6) |
Cytogen Corp. | Private | 1.82S | $8.19 | Cytogen placed 1.82M shares with the State of Wisconsin Investment Board at $4.50 per share, raising $8.19M (6/19) |
DepoMed Inc. | Private |
2.9S and 1.5W | $12.3 | DepoMed raised $12.3M with the placement of 2.9M shares and 1.5M warrants; investors were Easton Hunt Capital Partners LP and OrbiMed Advisors LLC, as well as S Squared Technology Corp. and Special Situations Funds; Fahnestock and Co. Inc. acted as placement agent (6/14) |
DNAPrint | Growth | N/A | $2 | Tampa Bay Financial committed to an additional $2M in growth capital (6/18) |
Gliatech Inc. | Equity | N/A | $2.5 | Gliatech received an additional $2.5M under its agreement with Paul Capital Royalty Acquisition Fund LP (6/27) |
Enzon Inc. | Private | N/A | $400 | Enzon plans to offer convertible subordinated notes worth $400M; the notes will be convertible into shares of Enzon stock; an overallotment option to issue an additional $60M in notes also may be exercised (6/14) |
Guilford | Private | 3S | $59 | Guilford raised $59M with the private placement of 3M shares with selected institutional investors, at a purchase price of $19.70 per share; CIBC World Markets Corp. served as placement agent (6/12) |
InKine | Private | N/A | $10 | InKine raised $10M from a private placement of 5.5% convertible subordinated notes due June 2003, along with warrants, with SAC Capital and SDS Capital Partners (6/18) |
Matritech Inc. | Private | 0.33S | $1.08 | Matritech sold 331,256 shares to Acqua Wellington North American Equities Fund Ltd. (6/4) |
Novogen Ltd. | Private | 10.5S | $11.2 | Novogen raised $11.2M with the issuance of 10.5M shares (6/1) |
Orchid | Private | 5.95S | $35.7 | Orchid sold 5.95M shares in a private placement; Robertson Stephens Inc. served as the placement agent and First Union Securities was co-placement agent; the financing was pursuant to a shelf registration filed in May (6/13) |
Ortec | Non-equity | N/A | _ | Ortec signed a letter of intent with the Paul Capital Royalty Acquisition Fund for $25M of non-equity capital based on the achievement of milestones (6/29) |
Procyon | Private | N/A | C$1 | Procyon completed the private placement with NATCAN and SIPAR (6/26) |
SangStat Inc. | Private | 1.36S | $15 | SangStat completed a private placement raising $15M through the sale of 1.36M shares to institutional investors at $11 per share (6/22) |
Sonus | Private | 1.7S | $4.9 | Sonus grossed $4.9M through a private placement of 1.7M shares with investors Orion Biomedical Fund, OrbiMed Advisors LLC and Perceptive Life Sciences Funds; Evolution Capital served as placement agent (6/18) |
Synsorb | Equity line | 1S | _ | Equity line agreement in which Synsorb may sell up to 1M shares of Oncolytics Biotech Inc. to Roseworth Group LLC over a 12-month period (6/1) |
Theratechnologies | Private | N/A | C$60 | Theratechnologies raised C$60M in a financing with Societe Generale de Financement de Quebec and the Solidarity Fund QFL (6/22) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
@ Dates refer to the date of the press release. |
||||
N/A = Not available or reported. |
||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||
